Dendrobine inhibits anaplastic thyroid cancer progression by targeting the JAK-STAT3 pathway - Scorecard - MDSpire

Dendrobine inhibits anaplastic thyroid cancer progression by targeting the JAK-STAT3 pathway

  • By

  • Yanhuan Shang

  • Dan Zhang

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: Dendrobine Suppresses Progression of Anaplastic Thyroid Carcinoma by Modulating the JAK-STAT3 Signaling Pathway

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with advanced Anaplastic Thyroid Carcinoma
Care Setting

Key Highlights

  • Dendrobine significantly reduces cell viability and proliferation in ATC cell lines (P < 0.001).
  • Inhibition of migration and invasion observed with dendrobine treatment (P < 0.05).
  • Dendrobine upregulates E-cadherin (P < 0.001) and downregulates N-cadherin and Vim (P < 0.05), indicating EMT inhibition.
  • In vivo studies show reduced tumor volume (P < 0.001) and improved liver function indices (P < 0.05) with dendrobine administration.
  • IL-6 pretreatment reverses the effects of dendrobine on JAK-STAT3 phosphorylation (P < 0.001).

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider dendrobine as a potential therapeutic candidate targeting the JAK-STAT3 pathway, possibly in combination with other therapies.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Dendrobine administered at doses of 10 or 40 mg/kg/d showed significant antitumor effects over a treatment duration of 21 days.

        Clinical Best Practices

        • Utilize dendrobine in conjunction with monitoring of the JAK-STAT3 pathway and assess for potential drug interactions.

        Related Resources & Content

        Original Source(s)

        Dendrobine inhibits anaplastic thyroid cancer progression by targeting the JAK-STAT3 pathway

        • by Yanhuan Shang, Dan Zhang

        • June 2, 2026

        Related Content

        Primary diffuse large B-cell lymphoma of the rectus abdominis muscle: a presumed primary case report and literature review

        HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee

        Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

        High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

        • by

        • June 1, 2026

        • 4 min